Lymphocytic choriomeningitis

Global Viral Hemorrhagic Fever Treatment Market to Surpass USD 2.20 Billion By 2031| Growth Market Reports

Retrieved on: 
Monday, June 12, 2023

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.

Key Points: 
  • The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.
  • Moreover, it provides crucial strategies that are helping market players to expand their market share.
  • For Any Questions on This Report: https://growthmarketreports.com/enquiry-before-buying/3851
    On the basis of region, the global viral hemorrhagic fever treatment market is classified as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
  • North America is projected to dominate the global market because it has a well-established R&D laboratory.

Global Viral Hemorrhagic Fever Treatment Market to Surpass USD 2.20 Billion By 2031| Growth Market Reports

Retrieved on: 
Monday, June 12, 2023

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.

Key Points: 
  • The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.
  • Moreover, it provides crucial strategies that are helping market players to expand their market share.
  • For Any Questions on This Report: https://growthmarketreports.com/enquiry-before-buying/3851
    On the basis of region, the global viral hemorrhagic fever treatment market is classified as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
  • North America is projected to dominate the global market because it has a well-established R&D laboratory.

FDA accepts HOOKIPA’s Investigational New Drug Application for HB-300 for the treatment of metastatic castration-resistant prostate cancer

Retrieved on: 
Monday, July 25, 2022

HB-300 is an alternating, 2-vector replicating arenaviral immunotherapy for metastatic castration-resistant prostate cancer.

Key Points: 
  • HB-300 is an alternating, 2-vector replicating arenaviral immunotherapy for metastatic castration-resistant prostate cancer.
  • There are several stages of prostate cancer, and prostate cancer cells usually need androgen hormones, such as testosterone, to grow.
  • Currently, there are limited treatment options for people with metastatic castration-resistant prostate cancer and only 30 percent will survive beyond five years.
  • HOOKIPAs pipeline includes its wholly owned investigational arenaviral immunotherapies targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs.

HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO

Retrieved on: 
Sunday, June 5, 2022

The data were presented in a poster presentation (abstract #2517) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • The data were presented in a poster presentation (abstract #2517) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • These results help focus our efforts as we move HB-202/HB-201 at the recommended Phase 2 dose into the Phase 2 portion of the trial.
  • Sixty-eight patients with advanced HPV16+ cancers were treated in the Phase 1 trial as of March 31, 2022.
  • Fifty-four patients had advanced HPV16+ head and neck cancers with a median of three prior therapies (range of 1-11), including a checkpoint inhibitor regimen in 50 of the 54.

Preclinical Data on Novel Arenaviral HIV Therapeutic Vaccines Presented at Keystone Symposium

Retrieved on: 
Friday, June 3, 2022

These data presented at the Keystone Symposium: Progress in Vaccine Development for Infectious Disease in Breckenridge, Colorado highlight robust and high-quality immune responses following administration of replicating arenaviral therapeutic vaccines.

Key Points: 
  • These data presented at the Keystone Symposium: Progress in Vaccine Development for Infectious Disease in Breckenridge, Colorado highlight robust and high-quality immune responses following administration of replicating arenaviral therapeutic vaccines.
  • These preclinical data highlight the potential of our novel arenaviral platform to deliver new options to treat HIV, said Joern Aldag, Chief Executive Officer at HOOKIPA.
  • Together, the preclinical data on the HIV arenaviral program support clinical development as a component of a potential HIV therapeutic.
  • Preclinical data in a separate poster presentation (poster 1019) showed the breadth and quality of the immune response with intramuscular administration of arenaviral therapeutic vaccines.

HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO

Retrieved on: 
Thursday, May 26, 2022

We look forward to sharing the full Phase 1 data results on our HB-200 program at ASCO.

Key Points: 
  • We look forward to sharing the full Phase 1 data results on our HB-200 program at ASCO.
  • The final analysis shows that HB-201 and 2-vector HB-202/HB-201 were generally well tolerated and showed anti-tumor activity in these difficult-to-treat patients.
  • The primary endpoint of Phase 1 is a recommended Phase 2 dose.
  • In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

HOOKIPA to present new preclinical, translational, and clinical biomarker data at AACR further supporting the potential of arenaviral platform in oncology

Retrieved on: 
Tuesday, March 8, 2022

The AACR posters provide a broad preclinical, translational, and clinical biomarker dataset highlighting the versatility and therapeutic utility of replicating arenavirus vectors to activate and augment tumor-specific CD8+ T cell responses for tumor killing.

Key Points: 
  • The AACR posters provide a broad preclinical, translational, and clinical biomarker dataset highlighting the versatility and therapeutic utility of replicating arenavirus vectors to activate and augment tumor-specific CD8+ T cell responses for tumor killing.
  • Specifically, the data support the potential of arenaviral vectors to target self and non-self tumor antigens and be used as monotherapy or in combination with other modalities.
  • The data demonstrate one strategy to unlock the potential of arenavirus vector-induced CD8+ T cell responses for tumor killing in a combination therapy with 4-1BB agonists.
  • HB-201 and HB-202 are HOOKIPAs lead oncology candidates engineered with the companys proprietary replicating arenaviral vector platform.

HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrolizumab for Treatment of Head and Neck Cancer and Reports FDA’s Fast Track Designation

Retrieved on: 
Tuesday, January 18, 2022

“Given our HB-200 clinical data to date, we believe that combining HB200 with pembrolizumab in earlier line settings has the potential--by inducing unprecedented levels of tumor antigen-specific CD8+ T cells--to overcome the limitations of checkpoint inhibitor monotherapy,” said Joern Aldag, Chief Executive Officer at HOOKIPA. “We’re eager to work closely with the FDA through the development process as we hope to bring new options to patients with HNSCC. Fast Track Designation for our lead oncology candidates is a great recognition of the promise of our versatile arenaviral platform to deliver novel immunotherapies which can address unmet needs in cancer.”

Key Points: 
  • Fast Track Designation for our lead oncology candidates is a great recognition of the promise of our versatile arenaviral platform to deliver novel immunotherapies which can address unmet needs in cancer.
  • Fast Track Designation is granted by the FDA for products that demonstrate the potential to address unmet medical needs in serious or life-threatening conditions.
  • Fast Track Designation was granted to the planned Phase 2 randomized trial of HB-201 and HB-202/HB-201 in combination with pembrolizumab for the treatment of 1st-line advanced/metastatic HPV16+ HNSCC.
  • The trial is evaluating HB-201 as a monotherapy, as an alternating 2-vector therapy with HB-202, and in combination with a PD-1 inhibitor.

HOOKIPA Pharma Reports Third Quarter 2021 Financial Results and Recent Highlights

Retrieved on: 
Wednesday, November 10, 2021

In August, pre-clinical data on HOOKIPAs arenaviral immunotherapeutic in melanoma was published in the peer-reviewed journal, Nature Communications.

Key Points: 
  • In August, pre-clinical data on HOOKIPAs arenaviral immunotherapeutic in melanoma was published in the peer-reviewed journal, Nature Communications.
  • The data reinforce the potential of HOOKIPAs arenaviral immunotherapeutic technology to activate and mobilize anti-tumor Tcells for effective control and eradication of established tumors.
  • On November9,2021 HOOKIPA provided a data update across its clinical development program.
  • HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies that mobilize and amplify targeted T cells to address unmet needs in cancer.

HOOKIPA announces publication on the benefits of its novel arenaviral immunotherapeutics in cancer in Frontiers in Oncology

Retrieved on: 
Thursday, October 14, 2021

We believe there is broad potential for our foundational arenavirus platform to deliver novel immunotherapies for a range of cancers.

Key Points: 
  • We believe there is broad potential for our foundational arenavirus platform to deliver novel immunotherapies for a range of cancers.
  • The article also reviews clinical data from the ongoing HB-201/HB-202 trial in people with advanced HPV16+ cancers.
  • HB-201 and HB-202 are HOOKIPAs lead oncology candidates engineered with the companys proprietary replicating arenaviral vector platform.
  • HOOKIPA is developing a broad pipeline of potential first-in-class arenaviral immunotherapies in oncology and infectious disease.